

01
venom of a snake of the Crotalus genus and which are essentially free from contaminating Fc as determined by immunoelectrophoresis using anti-Fc antibodies, and a pharmaceutically acceptable carrier, wherein said antivenom pharmaceutical composition neutralizes the lethality of the venom of a snake of the Crotalus genus.

02
41. (Twice Amended) The antivenom pharmaceutical composition of claim 40, wherein an antibody source for said Fab fragments is IgG(T).

42. (Twice Amended) The antivenom pharmaceutical composition of claim 40, wherein an antibody source for said Fab fragments is polyvalent IgG(T).

50 48. (New) The antivenom pharmaceutical composition of claim 40, wherein the Fab fragments are equine.

51 49. (New) The antivenom pharmaceutical composition of claim 40, wherein the antivenom pharmaceutical composition is lyophilized.

52 50. (New) The antivenom pharmaceutical composition of claim 40, further comprising thimerosal.

53 51. (New) An antivenom pharmaceutical composition for treating a snakebite victim, comprising Fab₂ fragments which bind specifically to a venom of a snake of the Crotalus genus and which are essentially free from contaminating Fc as determined by immunoelectrophoresis using anti-Fc antibodies, and a pharmaceutically acceptable carrier, wherein said antivenom pharmaceutical composition neutralizes the lethality of the venom of a snake of the Crotalus genus.

54 52. (New) A method of treating envenomation by a snake of the Crotalus genus comprising administering the antivenom pharmaceutical composition of any one of claims 40-42 and 48-51.

03
1.126
37 CFP
REVIEWED
FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com